Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone301-838-2500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$408.90 million
Profitability
Miscellaneous
Employees448
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions
What is Supernus Pharmaceuticals' stock symbol?
Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."
How were Supernus Pharmaceuticals' earnings last quarter?
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) announced its quarterly earnings results on Tuesday, August, 6th. The specialty pharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.56 by $0.05. The specialty pharmaceutical company earned $104.70 million during the quarter, compared to analyst estimates of $109.67 million. Supernus Pharmaceuticals had a return on equity of 22.36% and a net margin of 25.66%. The firm's quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.57 EPS. View Supernus Pharmaceuticals' Earnings History.
When is Supernus Pharmaceuticals' next earnings date?
What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?
Supernus Pharmaceuticals updated its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $400-410 million, compared to the consensus revenue estimate of $439.02 million.
What price target have analysts set for SUPN?
7 analysts have issued 12-month target prices for Supernus Pharmaceuticals' stock. Their forecasts range from $44.00 to $65.00. On average, they expect Supernus Pharmaceuticals' share price to reach $54.71 in the next year. This suggests a possible upside of 117.3% from the stock's current price. View Analyst Price Targets for Supernus Pharmaceuticals.
What is the consensus analysts' recommendation for Supernus Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Supernus Pharmaceuticals.
What are Wall Street analysts saying about Supernus Pharmaceuticals stock?
Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (10/9/2019)
- 2. Mizuho analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and are adjusting our price target to $18 from $3, based on the following factors: (1) adjustment to base year; (2) adjustment ot fully diluted share count; (3) accounting for the 1 for 15 reverse split; and (4) increasing our discount rate to 30% from our usual 15%, to account for increased perceived risk in developing drugs for both pancreatic cancer and AML. We note that there is still a relatively large delta between the current share price and our target, which is now also largely attributable to the low number of shares outstanding post-reverse split." (8/7/2019)
Has Supernus Pharmaceuticals been receiving favorable news coverage?
Media headlines about SUPN stock have been trending negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Supernus Pharmaceuticals earned a news sentiment score of -2.8 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Supernus Pharmaceuticals.
Are investors shorting Supernus Pharmaceuticals?
Supernus Pharmaceuticals saw a decrease in short interest in the month of September. As of September 30th, there was short interest totalling 5,580,000 shares, a decrease of 9.7% from the August 30th total of 6,180,000 shares. Based on an average daily volume of 533,300 shares, the days-to-cover ratio is currently 10.5 days. Currently, 11.0% of the shares of the stock are short sold. View Supernus Pharmaceuticals' Current Options Chain.
Who are some of Supernus Pharmaceuticals' key competitors?
Some companies that are related to Supernus Pharmaceuticals include Horizon Therapeutics (HZNP), The Medicines (MDCO), Ascendis Pharma A/S (ASND), United Therapeutics (UTHR), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), FibroGen (FGEN), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), Nektar Therapeutics (NKTR), Reata Pharmaceuticals (RETA), Taro Pharmaceutical Industries (TARO), Allakos (ALLK) and Alkermes (ALKS).
What other stocks do shareholders of Supernus Pharmaceuticals own?
Who are Supernus Pharmaceuticals' key executives?
Supernus Pharmaceuticals' management team includes the folowing people:
- Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 58)
- Mr. Gregory S. Patrick, Sr. VP & CFO (Age 68)
- Dr. Padmanabh P. Bhatt, Chief Scientific Officer & Sr. VP of Intellectual Property (Age 62)
- Dr. Stefan K. F. Schwabe, Chief Medical Officer and Exec. VP of R&D (Age 67)
- Dr. Todd Horich M.B.A., Ph.D., VP of Marketing
Who are Supernus Pharmaceuticals' major shareholders?
Supernus Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.98%), State of Alaska Department of Revenue (0.08%) and Pacer Advisors Inc. (0.04%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, Jack A Khattar, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View Institutional Ownership Trends for Supernus Pharmaceuticals.
Which institutional investors are selling Supernus Pharmaceuticals stock?
Which institutional investors are buying Supernus Pharmaceuticals stock?
How do I buy shares of Supernus Pharmaceuticals?
Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Supernus Pharmaceuticals' stock price today?
One share of SUPN stock can currently be purchased for approximately $25.18.
How big of a company is Supernus Pharmaceuticals?
Supernus Pharmaceuticals has a market capitalization of $1.32 billion and generates $408.90 million in revenue each year. The specialty pharmaceutical company earns $110.99 million in net income (profit) each year or $2.05 on an earnings per share basis. Supernus Pharmaceuticals employs 448 workers across the globe.View Additional Information About Supernus Pharmaceuticals.
What is Supernus Pharmaceuticals' official website?
How can I contact Supernus Pharmaceuticals?
Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]
MarketBeat Community Rating for Supernus Pharmaceuticals (NASDAQ SUPN)
MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe SUPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SUPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
